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Oncogene-induced senescence is considered to act as a potent barrier to cell transformation, and has been
seen in vivo during the early stages of tumor development. Human nevus cells frequently express oncogenic N-
RAS or B-RAF, and are thought to be permanently growth arrested. Many studies have suggested that the
p16INK4a and, to a lesser extent, the p14ARF tumor suppressor proteins act as critical triggers of oncogene-
induced senescence in nevi, and thus these proteins represent major inhibitors of progression to melanoma.
There have also been reports, however, showing that p16INK4a and/or p14ARF is not sufficient to execute the
oncogene-induced senescence program. In this study, we examined the impact of melanoma-associated
N-RASQ61K on melanocyte senescence and utilized RNA-interference vectors to directly assess the individual
contribution of human p14ARF and p16INK4a genes to the N-RAS-induced senescence program. We formally
show that cultured human melanocytes can initiate an effective oncogene-mediated senescence program in the
absence of INK4a/ARF-encoded proteins. Our data are consistent with observations showing that senescent
nevus cells do not always express p16INK4a, and highlight the need to thoroughly explore INK4a/ARF-
independent molecular pathways of senescence in human melanocytes.
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INTRODUCTION
Aberrant activation of the RAS-RAF-mitogen-activated pro-
tein kinase pathway is present in the majority of human nevi
and melanomas. Approximately 20% of human melanomas
harbor oncogenic N-RAS mutations (Chin et al., 2006), and a
further 60% have activating mutations in the protein kinase
and the downstream RAS effector, B-RAF (Goydos et al.,
2005). The activation of the RAS signaling cascade is not
sufficient to induce melanoma, however, as cells in 80% of
benign nevi express oncogenic B-RAF or N-RAS (Dong et al.,
2003; Pollock et al., 2003; Kumar et al., 2004; Poynter et al.,
2006; Bauer et al., 2007). These data can be reconciled by
the observation that an aberrant RAS signaling triggers
premature senescence (Serrano et al., 1997), which is also
seen in vivo during the early stages of human and mouse
tumor development (Braig et al., 2005; Chen et al., 2005;
Collado et al., 2005; Michaloglou et al., 2005; Gray-Schopfer
et al., 2006). In particular, it has been suggested that human
nevi contain senescent cells that are not found among normal
skin melanocytes or advanced melanomas (Michaloglou
et al., 2005; Gray-Schopfer et al., 2006). It should be noted,
however, that the presence of senescent nevus cells in vivo
remains controversial (Cotter et al., 2007, 2008; Michaloglou
et al., 2008).
The molecular mechanisms that trigger oncogene-induced
senescence in nevi are thought to represent critical inhibitors
of progression to melanoma, and many studies implicate the
p16INK4a and, to a lesser extent, the p14ARF tumor suppressor
proteins in melanocyte senescence. These tumor suppressors
are encoded by the single INK4a/ARF genomic sequence that
is altered in 30–70% of melanomas (Sharpless and Chin,
2003) and is inherited in mutated form in approximately 39%
of melanoma-prone kindreds (Goldstein et al., 2006b).
Although both p16INK4a and p14ARF are altered in human
tumors and melanoma-prone families, it appears that
p16INK4a is the principal INK4a/ARF melanoma susceptibility
gene in humans (Goldstein et al., 2006b). More than 50
disease-associated germline mutations specifically targeting
p16INK4a have been identified in over 150 familial melanoma
kindreds (Goldstein et al., 2006a), and the INK4a/ARF locus
is the most common site of deletion in established
melanomas (Curtin et al., 2005).
p16INK4a inhibits the activities of cyclin D-dependent
kinases, CDK4 and CDK6, to prevent the hyperphospho-
rylation of the retinoblastoma protein, pRb (Serrano et al.,
1993), whereas p14ARF activates the p53 pathway by
binding and inhibiting the p53-ubiquitin ligase, hdm2
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Thus, the loss of INK4a/ARF simulates the simultaneous
inactivation of the pRb and p53 pathways, and mice with
melanocyte-specific expression of oncogenic H-RASG12V and
lacking INK4a/ARF develop cutaneous melanomas with a
high penetrance (Chin et al., 1997). Similarly, normal human
fibroblasts derived from melanoma-prone individuals carry-
ing alterations affecting both p16INK4a and p14ARF or
p16INK4a were resistant only to oncogenic RAS-induced
senescence (Huot et al., 2002; Jones et al., 2007). The
specific silencing of the p16INK4a expression in human
fibroblasts also allowed the escape from H-RAS-induced
senescence (Bond et al., 2004) and prevented the silencing of
E2F targets (Narita et al., 2003). Further, the central role of
p16INK4a in melanocyte senescence was recently implicated
in a genome-wide screen that identified 16 unique genes that
not only were required for BRAFV600E-mediated senescence,
but were also necessary for BRAFV600E-mediated induction of
p16INK4a (Wajapeyee et al., 2008).
Intriguingly, several studies suggest that p16INK4a and/or
p14ARF are not sufficient to execute the oncogene-induced
senescence program. Growth-arrested nevi occur in melano-
ma-prone patients who are homozygous for p16INK4a (and
possibly p14ARF) deficiency, although the nevi in these
patients are more numerous and larger than those in
individuals with wild-type p16INK4a (Gruis et al., 1995).
Senescent nevus cells do not always express p16INK4a
(Michaloglou et al., 2005), and p16INK4a silencing did not
bypass B-RAF- or H-RAS-induced senescence in human
fibroblasts (Voorhoeve and Agami, 2003; Michaloglou et al.,
2005). Short-term H-RAS expression also permanently growth
arrested human fibroblasts lacking the p14ARF expression
(Voorhoeve and Agami, 2003). Perhaps the most informative
study comes from the expression of oncogenic H-RAS or B-
RAF in human epidermal melanocytes (HEMs). As expected,
short-term oncogene expression arrested the proliferation of
melanocytes, and this was associated with cellular senes-
cence and the induction of p16INK4a (p14ARF was not
analyzed). Despite this, the inactivation of p16INK4a by highly
effective short hairpin RNAs (shRNAs) did not prevent
H-RAS- or B-RAF-induced melanocyte cell-cycle arrest
or cell vacuolization, a marker of cellular senescence
(Denoyelle et al., 2006).
Numerous explanations can account for the reported
differences regarding the contribution of p16INK4a and
p14ARF to oncogene-induced senescence. First, the over-
expression of mutant oncogenes, such as B-RAF or H-RAS,
may vary in their mechanism of senescence activation. For
instance, oncogenic N-RAS and B-RAF modulate a different
suite of genes (Bloethner et al., 2005). Further, H-RAS, but not
its downstream target B-RAF, engaged a senescence program
mediated by the massive expansion of the endoplasmic
reticulum (ER) (Denoyelle et al., 2006). This ER-stress-
mediated senescence may be less important in melanoma,
as there is a general preference for B-RAF and N-RAS, but not
H-RAS, mutations in this cancer (Davies et al., 2002; Goydos
et al., 2005). Second, most studies utilize human fibroblasts,
not melanocytes, but melanomas are predominant in human
carriers of INK4a/ARF alterations. Third, in reports utilizing
fibroblasts derived from melanoma-prone kindreds, it is
difficult to exclude alterations in other key senescence
regulators. Therefore, in this report, we utilized RNA-
interference vectors in normal human melanocytes to directly
assess the individual contribution of human p14ARF and
p16INK4a genes to the N-RAS-induced senescence program.
RESULTS AND DISCUSSION
To evaluate the response of primary human melanocytes to
oncogenic N-RAS, the wild-type N-RAS and the melanoma-
associated N-RASQ61K mutant were stably transduced into
HEMs. The accumulation of N-RAS was detected 5 days post-
transduction, and the impact of N-RAS on melanocyte
proliferation was monitored over 15 days. We focused our
analyses on the two major RAS effector pathways that have a
critical role in human cancer: the extracellular signal-
regulated (ERK) mitogen-activated protein kinase pathway
that is activated when RAS interacts and stimulates the RAF
family of protein kinases (including B-RAF) and the AKT
pathway that is stimulated by RAS-mediated activation of the
phosphatidylinositol-3-OH lipid kinase (reviewed in Shaw
and Cantley, 2006). As expected, the accumulation of the co-
expressed Copepod GFP (copGFP) did not induce ERK or AKT
activation (Figure 1a). In contrast, N-RAS-transduced mela-
nocytes accumulated increased levels of phosphorylated ERK
that, along with phosphorylated AKT, were significantly
higher and seen earlier (5 days post-transduction) in cells
expressing the constitutively active, oncogenic N-RASQ61K
(Figure 1a). Furthermore, N-RASQ61K-transduced melano-
cytes expressed levels of phosphorylated ERK 10 and 15
days post-infection, comparable with the NM39 human
melanoma cells (Figure 1b) that express the constitutively
active B-RAFV600E (data not shown). The accumulation of
oncogenic N-RASQ61K, but not the wild-type N-RAS, protein
in human melanocytes also increased the expression of the
CDK inhibitors, p16INK4a and p21Waf1, whereas p53 levels
were increased only at the earlier time points (5 and 10 days
post-transduction) by both the wild-type and oncogenic N-
RAS proteins (Figure 1a).
The expression of p14ARF was not detectable in melano-
cytes by western blot analysis (data not shown), but the
transcript was detectable by reverse transcriptase PCR (RT-
PCR), and the levels of p14ARF mRNA, as determined using
real-time PCR, increased slightly (between two- and threefold
above the copGFP control transduction) in response to
N-RASQ61K, 5 days post-induction (Figure 1c). In comparison,
the p16INK4a transcript was potently induced by N-RASQ61K,
and increased almost sevenfold, 5 days after infection. The
fact that mouse p19ARF expression is significantly increased
by oncogenic RAS (between 5- and 10-fold) (Palmero et al.,
1998) may explain the apparent differences between the
mouse and human ARF proteins in their relative contribution
to melanoma tumorigenesis. Murine ARF is the major INK4a/
ARF tumor suppressor protein, and oncogenic N-RAS
collaborates with ARF deficiency to fully transform melano-
cytes (Ha et al., 2007). In contrast, the role of human p14ARF
in tumorigenesis remains controversial, although it does not
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have a protective role against RAS-induced transformation of
human fibroblasts (Voorhoeve and Agami, 2003).
As expected, melanocytes expressing N-RASQ61K ceased
proliferating 5 days after infection (Figure 2a), and acquired
a positive senescence-associated b-galactosidase activity
(SA-b-Gal; Figure 2b); 69% of N-RASQ61K melanocytes stained
positive for SA-b-Gal 15 days post-transduction. In fact, the
majority of N-RASQ61K-transduced melanocytes displayed
several markers of oncogene-driven senescence, namely, cell
flattening, increase in cellular size, senescence-associated
heterochromatin foci, and significantly decreased 5-bromo-
deoxyuridine (BrdU) incorporation (Figure 2a and c). Wild-
type N-RAS induced an intermediate level of proliferative
arrest compared with oncogenic N-RAS (Figure 2a), which
was not associated with all markers of senescence (Figure 2).
In particular, melanocytes expressing wild-type N-RAS or the
copGFP control did not show chromatin remodeling and the
wild-type N-RAS showed minimal b-galactosidase activity
(Figure 2b and c). The ER-associated unfolded protein
response (UPR), which is associated with H-RAS senescence
(Denoyelle et al., 2006), did not appear to contribute
significantly to N-RASQ61K-induced melanocyte senescence.
Specifically, only a minor proportion (o5%) of N-RASQ61K
melanocytes displayed intracellular vacuolization (Figure 2c),
and there was no N-RAS-associated increase in the UPR
sensor Grp78 (Figure 1a), which did increase in melanoma
cells treated with the classic ER-stress inducer, tunicamycin
(Figure 2d) (Schroder and Kaufman, 2005; Jiang et al., 2007).
These data confirm that the UPR is specific to H-RAS and is
not a feature of N-RAS-induced senescence. Accordingly,
nevi with N-RAS-mutated cells expressed lower levels of
Grp78 than the H-RAS mutant, Spitz nevi (Denoyelle et al.,
2006). The reduced ability of N-RASQ61K to promote UPR is
because of its diminished activation of AKT, which is potently
activated by H-RAS and is the main driver of H-RAS-
mediated UPR and senescence in melanocytes (Denoyelle
et al., 2006). Our results confirm that N-RAS-mediated
senescence does not involve UPR, and is associated with,
but not necessarily caused by, the induction of p16INK4a and,
to a lesser extent, p14ARF.
There is evidence to suggest that the intensity and duration
of oncogenic signaling determine the cellular response.
Sustained and high activation of the mitogen-activated
protein kinase and AKT pathways drive melanocytes into
the senescence program, whereas weaker signals induce
melanocyte proliferation (Cheung et al., 2008; Leikam et al.,
2008). This notion has been reinforced through the analyses
of melanoma tumors, which frequently express activated
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Figure 1. Oncogenic N-RASQ61K activates the mitogen-activated protein kinase and AKT pathways and upregulates p16INK4a and p14ARF expression in
melanocytes. (a) Expression of the indicated proteins was determined by western blot analysis at 5, 10, and 15 days after infection of human epidermal
melanocytes with lentiviruses expressing N-RASQ61K, wild-type N-RAS, or copGFP control. (b) Human epidermal melanocytes (HEMs) were infected with
lentiviruses expressing N-RASQ61K or copGFP, and after 15 days the expression levels of total and phosphorylated ERK (p-ERK) were compared with those
observed in the NM39 melanoma cell line, which expresses the constitutively active B-RAFV600E oncogene. All lanes in this analysis were derived from a single
gel and western blot. (c) Expression of p14ARF and p16INK4a mRNA was analyzed using RT-PCR in melanocytes (M) and human fibroblasts (F). Reactions always
included a negative water control () (top panel). The fold change in p14ARF and p16INK4a transcript levels in melanocytes transduced with N-RASQ61K-
expressing lentivirus was analyzed using real-time PCR 3 and 5 days after infection. Transcript levels were normalized against the copGFP control transductions
(bottom panel) and correspond to the mean fold change±SD.
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AKT3 (Stahl et al., 2004) and oncogenic B-RAFV600E (Uribe
et al., 2003). Deregulated AKT3 phosphorylates oncogenic
B-RAF and reduces its activity and that of the mitogen-
activated protein kinase pathway to levels that promote
proliferation (Cheung et al., 2008). Thus, the co-expression of
B-RAFV600E and AKT3 in immortalized murine melanocytes
significantly enhanced anchorage-independent growth be-
yond the growth achieved by expressing either of these genes
(Cheung et al., 2008). In the context of our study, oncogenic
signaling was sustained (both AKT and ERK remained active
15 days post-infection with N-RASQ61K) and intense (p21WafI
induction is a marker of high oncogenic signaling in
melanocytes (Leikam et al., 2008), and p21Waf1 expression
remained high in response to N-RASQ61K) (see Figure 1a).
Thus, our cell model resembles melanocytes in benign nevi;
these cells frequently express constitutively active B-RAF or
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N-RAS (Pollock et al., 2003; Bauer et al., 2007), accumulate
low levels of active AKT3 (Stahl et al., 2004), and are growth
arrested (Michaloglou et al., 2005).
To determine whether N-RAS-induced senescence of
human melanocytes required the INK4a/ARF-encoded pro-
teins, we applied lentiviral shRNA vectors that specifically
suppress the expression of p16INK4a, p14ARF, or both
p16INK4a and p14ARF by targeting sequences from their
unique first exons or by targeting sequences from the shared
exon 2 (Figure 3a). To minimize the confounding effects of
shRNA off-target silencing, at least two independent silencing
molecules targeting each transcript were generated. These
molecules were highly effective in silencing the expression of
p16INK4a and/or p14ARF, as shown by shRNA transduction of
the NM179 melanoma cell line, which carries an intact
INK4a/ARF locus (Rizos et al., 1999), and by analysis of the
protein expression 3 days post-infection (Figure 3b).
HEM1455 melanocytes were transduced with these shRNA
molecules, and 3 days post-infection the cells were
re-transduced with lentiviral vectors expressing N-RASQ61K
or copGFP. In all experiments, we also applied a negative
control shRNA molecule without homology to any human
gene.
The inhibition of the p16INK4a expression did not alter the
growth arrest induced by oncogenic N-RASQ61K, and
surprisingly the melanocytes were arrested after infection
regardless of the p16INK4a status (15 days after infection, only
3% of p16INK4a-silenced N-RASQ61K melanocytes had in-
corporated BrdU, compared with 39% of p16INK4a-silenced
copGFP control melanocytes; Figure 4a). Similarly, cellular
senescence was initiated and maintained in the presence or
absence of p16INK4a expression; approximately, 70% of
melanocytes were positive for SA-b-Gal activity irrespective
of the p16INK4a status (Figure 4a), and the two different
p16INK4a-specific shRNAs exerted similar effects (Figure 4a,
lower panel). However, not all the markers of senescence
were present in the p16INK4a-null melanocytes. Specifically,
the percentage of N-RASQ61K-expressing cells with senes-
cence-associated heterochromatin foci was clearly reduced
in the absence of p16INK4a (36% of p16INK4aþ cells showed
foci versus 18% of p16INK4a cells; Figure 4a). These foci
result in the stable repression of some E2F target genes and
are involved in the irreversible growth arrest associated with
senescence (Narita et al., 2003). Each focus in a senescent
cell results from the condensation of an individual chromo-
some, and is enriched for common markers of heterochro-
matin, including histone H3 methylated at lysine 9 and
the non-histone chromatin protein, HMGA2 (Figure 4b)
(reviewed in Adams, 2007). No other marker of senescence,
including cell morphology, SA-b-Gal activity, or BrdU index,
discriminated between p16INK4a-intact and p16INK4a-null
senescent melanocytes.
N-RASQ61K-induced senescence in melanocytes was also
not bypassed by silencing the p14ARF expression or by
silencing p14ARF and p16INK4a, using the exon 2-specific
(Figure 4a) or the combination of a p16INK4a-specific and
p14ARF-specific shRNA molecule (Figure 4a, lower panel).
Elevated levels of p53 were maintained over the 15-day
transduction period in the INK4a/ARF-null melanocytes
(compare Figures 1a and 4c), suggesting that the activation
of the p53 pathway may play a key role in promoting RAS-
induced senescence in the absence of p16INK4a and/or ARF.
We are currently investigating the co-operative roles of the
p53 and p16INK4a pathways in maintaining melanocyte
senescence.
Importantly, p53 levels were not significantly reduced in
the absence of p14ARF (see Figure 4c), suggesting that ARF is
not a critical regulator of p53 in unstressed human
melanocytes. It should be noted that the expression of ARF
is tightly repressed and largely undetectable during embry-
ogenesis and post-natal development (Zindy et al., 1997,
2003; McKeller et al., 2002), and certainly not detectable in
human melanocytes even after oncogenic RAS expression
(data not shown). In addition, in unstressed cells, ARF is
sequestered within the nucleolus, where it is restricted from
activating p53 (Korgaonkar et al., 2005). Therefore, it seems
unlikely that ARF modulates p53 in normal proliferating cells
and it appears that in response to oncogenic stimuli, human
cells induce p53 in a p14ARF-independent manner (Voor-
hoeve and Agami, 2003).
It is widely proposed that the p14ARF and p16INK4a
melanoma tumor suppressor proteins function to protect
melanocytes from oncogenic transformation (reviewed in
Ben-Porath and Weinberg, 2005). In this report, we have
formally proven that cultured human melanocytes can
initiate an oncogene-mediated senescence program in the
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absence of INK4a/ARF-encoded proteins. It is worth noting
that this senescence program was initiated in cultured
melanocytes maintained in media that were supplemented
with many growth factors, including cholera toxin and 12-O-
tetradecanoylphorbol-13-acetate. Considering that culture
conditions can influence the growth rate and life span of
human melanocytes (Sviderskaya et al., 2003), we cannot
exclude the possibility that cultured melanocytes and
melanocytes in vivo differ in their response to oncogenic
stress. Nevertheless, our data are consistent with observations
showing that senescent nevus cells with oncogenic B-RAF do
not always accumulate p16INK4a (Michaloglou et al., 2005),
and growth-arrested nevi occur in p16INK4a-deficient mela-
noma-prone patients (Gruis et al., 1995). Our results also
reinforce the notion that p16INK4a is the major cell-cycle
regulator of the human INK4a/ARF locus. The single knock-
down of p14ARF was completely inactive, whereas the loss
of p16INK4a function appears to have weakened the integrity
of the pRb pathway and reduced the formation of hetero-
chromatic foci, and perhaps the stability of the senescent
state. This raises the possibility that p16INK4a may synergize
with another molecule or pathway to protect melanocytes
against oncogenic stress. Certainly, in human fibroblasts, the
combined loss of p16INK4a and p53 functions, but not the
single knockdown of either, permitted anchorage-indepen-
dent outgrowth and tumor formation (Voorhoeve and Agami,
2003). Moreover, p53 and p21Waf1 levels were elevated in
senescent p16INK4a-deficient melanocytes, but not in senes-
cent normal melanocytes (Sviderskaya et al., 2003). These
data mandate a careful exploration of the INK4a/ARF-
dependent and -independent pathways of senescence induc-
tion in cells of melanocytic lineage.
MATERIALS AND METHODS
Cell culture
Human NM39, NM47, and NM179 melanoma cells (Rizos et al.,
1999), SK-Mel 28 melanoma cells, HEK293T and HDF1314 human
fibroblast cells (Cell Applications, San Diego, CA) were grown in
DMEM (Gibco BRL, Carlsbad, CA) supplemented with 10% fetal
bovine serum and glutamine. HEMs were obtained from Cell
Applications and grown in HAM’s F10 media, supplemented with
ITS premix (Becton Dickinson, Franklin Lakes, NJ), 12-O-tetradeca-
noylphorbol-13-acetate, IBMX, cholera toxin, 20% fetal bovine
serum, and glutamine (modified from Halaban et al., 1986). All cells
were cultured in a 37 1C incubator with 5% CO2. The melanoma
cells were treated with the ER-stress inducer, tunicamycin (5 mM;
Sigma, St Louis, MO), for 24 hours.
Lentivirus transductions
Lentiviruses were produced in HEK293T cells using the pSIH1-H1-
copGFP (Copepod green fluorescent protein) shRNA expression
vector or the pCDH-CMV-MCS-EF1-copGFP lentiviral vector (Sys-
tems Biosciences, Mountain View, CA) encased in viral capsid
encoded by three packaging plasmids as described earlier (Dull
et al., 1998). The viruses were concentrated as described earlier
(Reiser, 2000). Viral titers were determined using 1 105 U2OS cells
per well in six-well plates and transduced with serial dilutions of the
concentrated viral stocks in the presence of Polybrene (8 mgml1;
Sigma). The cells were harvested 48 hours post-transduction,
analyzed by flow cytometry for GFP expression, and viral titer
calculated. The cells were infected using a multiplicity of infection
of 5–10 to provide an infection efficiency above 90%.
Constructs
The N-RAS and B-RAF oncogenes were cloned into the pCDH-CMV-
MCS-EF1-copGFP lentiviral vector that co-expresses copGFP. The
p16INK4a (exon 1a)-directed shRNA sequences correspond to
nucleotides 236–250 and 288–306 (Voorhoeve and Agami, 2003)
(GenBank accession number NM_000077). The p14ARF (exon 1b)-
directed shRNA sequences correspond to nucleotides 157–175
(Voorhoeve and Agami, 2003) and 332–350 (GenBank accession
number NM_058195). The shRNA sequences targeting both p14ARF
and p16INK4a correspond to nucleotides 627–645 (INK4a/ARF exon
2) (Voorhoeve and Agami, 2003) (GenBank accession number
NM_000077).
The non-silencing negative control shRNA did not show
complete homology to any known human transcript and had the
following sequence: 50-TTAGAGGCGAGCAAGACTA-30.
Western blotting
Total cellular proteins were extracted at 4 1C using the RIPA lysis
buffer containing protease inhibitors (Roche, Basel, Switzerland).
The proteins (30–50 mg) were resolved on 12% SDS-PAGE and
transferred to Immobilon-P membranes (Millipore, Bedford, MA).
Western blots were probed with antibodies against p16INK4a (N20;
Santa Cruz, Santa Cruz, CA), p21Waf1 (C-19; Santa Cruz), Grp 78
(H129; Santa Cruz), b-actin (AC-74; Sigma-Aldrich, St Louis, MO),
p53 (DO-1; Santa Cruz), phosphorylated ERK (E4; Santa Cruz), ERK
(137F5; Cell Signalling, Danvers, MA), phosphorylated AKT (L32A4;
Cell Signalling), AKT (11E7; Cell Signalling), p14ARF (DCS-240;
Sigma), c-MYC (A14; Santa Cruz), histone H3 methylated at lysine 9
(Millipore), and HMGA (FL109; Santa Cruz).
Indirect immunofluorescence
Cultured cells (3–4 104) seeded on coverslips in 12-well plates
were washed in phosphate-buffered saline and fixed in 2%
formaldehyde, 0.2% glutaraldehyde, 7.4mM Na2HPO4, 1.47mM
KH2PO4, 137mM NaCl, and 2.68mM KCl. The cells were then
rinsed three times with phosphate-buffered saline, and SA-b-Gal
activity was detected as described earlier (Dimri et al., 1995). The
same cells were immunostained for 50 minutes with an antibody to
BrdU (BU-1; Amersham Biosciences, Piscataway, NJ) followed by a
50-minute exposure to Alexa Fluor 594-conjugated secondary IgG
(Molecular Probes, Carlsbad, CA). For BrdU staining, the cells were
exposed to BrdU for 12–16 hours, fixed as detailed above, and then
treated for 20 minutes with approximately 7U RQ1 DNase
(Promega, Madison, WI). Nuclear DNA was stained with 1 mgml1
of 4’,6-diamidino-2-phenylindole for 10–15 minutes.
RNA extraction and cDNA synthesis
RNA was extracted from HEM1455 human primary melanocytes and
HDF1314 human primary fibroblasts using Trizol (Sigma) and treated
with RQ1 DNase (Promega) to remove genomic DNA. cDNA was
synthesized according to the manufacturer’s protocol from 1 mg of
RNA using Superscript III (Invitrogen, Carlsbad, CA) with oligo-dT
primers. No-Superscript III enzyme controls were performed to
confirm that there was no contaminating genomic DNA.
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RT-PCR and quantitative real-time RT-PCR
cDNA (100 ng) was amplified using the TaqF1 polymerase (Fischer
Biotech) using 1 buffer provided, 200 nM dNTPs, 300 nM primers,
5U Taq, 1.5mM MgCl2, and 4% DMSO. The PCR cycling conditions
were 30 cycles at 95 1C for 30 seconds, 52 1C for 30 seconds, and
72 1C for 1 minute, then for 10 minutes at 72 1C. PCR products were
run on 1.2% agarose gel and visualized with ethidium bromide.
RT-PCR primers were
p14ARF fwd: AGTGGCGCTGCTCACCTC
p16INK4a fwd: CAGCACCGGAGGAAGAAAG
Common rev: AAAACTACGAAAGCGGG
The fold change in p14ARF and p16INK4a transcript levels in
HEM1455 cells transduced with N-RASQ61K was analyzed using
real-time PCR at 3 and 5 days after transfection with oncogenic RAS.
The transcript levels were normalized against the GFP control
transductions. Real-time RT-PCR was performed using a Corbett
Rotorgene 3000 with Platinum qPCR SuperMix-UDG (Invitrogen)
with 100 ng of cDNA, 250 nM of each primer, 100 nM of probe, 1%
DMSO, and 0.5mM of BSA in a final volume of 20 ml. The primers
used were
p16INK4a fwd: GCCCAACGCACCGAATAG
p16INK4a rev: ACGGGTCGGGTGAGAGTG
p16INK4a probe: FAM6-TCATGATGATGGGCAGCGCC-TAMRA
(A/B 450025)
p14ARF fwd: CTACTGAGGAGCCAGCGTCT
p14ARF rev: ACGGGTCGGGTGAGAGTG
p14ARF probe: FAM6-TCATGATGATGGGCAGCGCC-TAMRA
(A/B 450025)
We confirmed that the primers amplified the appropriate
products, using cell lines with known levels of expression of the
genes, under real-time PCR conditions. The samples were collected
from two separate experiments, with each sample run in duplicate
on two separate occasions. Cycle threshold numbers (Ct) were
recorded from the exponential phase of PCR amplification. The
relative expression of each gene was compared back with a standard
curve included with each run. Equal loading was ensured by
adjusting samples to the same average expression levels for the
ribosomal protein 18S using the VIC-labeled PDAR probes (Applied
Biosystems, Foster City, CA). The results were averaged, and then
normalized against the GFP control transductions.
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